The Company > Investors
NovaBiotics has raised >£5 m in private equity funding to date and with this, has successfully delivered its lead product, Noveaxtin® to the clinic. A supporting and robust pipeline of medicinal and consumer-health care focused technologies (see luminaderm.com) have also been developed in parallel. The board and management are focused on high-value opportunities and delivery of commercial success from the Company’s solid technology base.
NovaBiotics aims to complete preclinical and early clinical R&D for each indication and to then form strategic alliances and/or out-licensing partnerships with appropriate pharmaceutical/biopharmaceutical entities for later stage clinical and regulatory development, manufacture and marketing. Revenue from such alliances will be re-invested into pipeline development and growth of the technology base which in turn, will pave the way for additional revenue generating alliances. This step-wise market penetration strategy will generate a steady income stream to facilitate expansion of the company in such as way as to build significant value and maximize investor returns.
Registered in Scotland No. SC272344. Registered Address: NovaBiotics Ltd, Cruickshank Building, Craibstone, Aberdeen, AB21 9TR, UK
© NovaBiotics Ltd 2009.
All Rights Reserved
Last updated
22 October, 2009
